GLP-1 Receptor Targeting in Diabetic and Healthy Individuals

Radboud University Medical Center20 enrolled

Overview

The purpose of the study is to determine whether there are differences in pancreatic uptake of the radiotracer between healthy individuals and patients with type 1 diabetes. If T1D patients have a markedly reduced uptake, the compound may be suitable for estimation of pancreatic beta cell mass, i.e. the cells in the pancreas that produce insulin.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Type 1 Diabetes

Interventions

radiolabeled ExendinOTHER

Eligibility

Sex: ALLMin age: 21 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * type 1 Diabetes Exclusion Criteria: * breast feeding * pregnant

Locations (1)

Radboud University Nijmegen Medical Center

Nijmegen, Gelderland, Netherlands

Outcomes

Primary Outcomes

pancreatic uptake of radiolabeled Exendin

uptake will be given as counts per MBq injected activity as determined by calibrated SPECT/CT scanner with attenuation correction.

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.